# Glenmark Pharmaceuticals (NSE: GLENMARK) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/GLENMARK · Pivot · prices to 22 Oct 2026

Glenmark Pharmaceuticals (NSE: GLENMARK) closed at ₹2,196.40 on 22 Oct 2026, down 0.16% on the day. With a market capitalisation of ₹61,909 Cr, it ranks 159th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 45.5× trailing earnings, against a return on equity of 13.0% in FY26. Over the past year the share price has risen 16.4%. Its 52-week range is ₹1,792.60 (28 Oct 2025) to ₹2,537.60 (28 Aug 2026); the last close is 13.4% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹3,932 Cr (+28.5% year on year) and net profit ₹483 Cr (+928.0%), on a consolidated basis. Promoters held 46.65% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹2,196.40 |
| Market cap | ₹61,909 Cr |
| P/E (trailing) | 45.5 |
| ROE | 13.0% (FY26) |
| ROCE | 33.0% (FY26) |
| Debt to equity | 0 |
| 52-week high | ₹2,537.60 (28 Aug 2026) |
| 52-week low | ₹1,792.60 (28 Oct 2025) |
| 1-year return | +16.4% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹3,932 Cr | +28.5% | ₹483 Cr | +928.0% | ₹17.11 |
| Q4 FY26 | ₹3,760 Cr | +16.8% | ₹301 Cr | +6,779.5% | ₹10.68 |
| Q3 FY26 | ₹3,888 Cr | +17.8% | ₹403 Cr | +15.9% | ₹14.29 |
| Q2 FY26 | ₹6,004 Cr | +76.6% | ₹610 Cr | +72.2% | ₹21.63 |
| Q1 FY26 | ₹3,059 Cr | −5.1% | ₹47 Cr | −86.2% | ₹1.66 |
| Q4 FY25 | ₹3,220 Cr | +5.1% | ₹4 Cr | — | ₹0.16 |
| Q3 FY25 | ₹3,302 Cr | +31.7% | ₹348 Cr | — | ₹12.33 |
| Q2 FY25 | ₹3,401 Cr | +6.0% | ₹354 Cr | — | ₹12.55 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹13,322 Cr | ₹1,047 Cr |
| FY24 | ₹11,813 Cr | −₹1,434 Cr |
| FY23 | ₹12,990 Cr | ₹377 Cr |
| FY22 | ₹12,305 Cr | ₹994 Cr |
| FY21 | ₹10,944 Cr | ₹970 Cr |
| FY20 | ₹10,641 Cr | ₹776 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 46.65%
- Foreign institutions: 20.89%
- Domestic institutions: 18.60%
- Non-institutions: 13.81%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Max Healthcare Institute](https://app.pivotnow.in/stock/MAXHEALTH) | ₹804.80 | ₹79,237 Cr | 54.6 | 13.4% |
| [Alkem Laboratories](https://app.pivotnow.in/stock/ALKEM) | ₹4,972.00 | ₹59,304 Cr | 25.8 | 16.6% |
| [Aster DM Health](https://app.pivotnow.in/stock/ASTERDM) | ₹647.20 | ₹57,086 Cr | 101.1 | 8.5% |
| [Fortis Healthcare](https://app.pivotnow.in/stock/FORTIS) | ₹720.15 | ₹54,659 Cr | 52.3 | 10.5% |
| [Abbott India](https://app.pivotnow.in/stock/ABBOTINDIA) | ₹25,445.00 | ₹53,931 Cr | 34.8 | 33.4% |
| [Biocon](https://app.pivotnow.in/stock/BIOCON) | ₹332.85 | ₹53,829 Cr | 117.6 | 1.1% |

## Questions and answers

### What is the share price of Glenmark Pharmaceuticals today?

Glenmark Pharmaceuticals (NSE: GLENMARK) last closed at ₹2,196.40 on 22 Oct 2026. Its 52-week high is ₹2,537.60 and its 52-week low is ₹1,792.60.

### What is the market cap of Glenmark Pharmaceuticals?

Glenmark Pharmaceuticals' market capitalisation is ₹61,909 Cr (₹61,909 Cr) at the 22 Oct 2026 close, ranking 159th among the NSE companies Pivot tracks.

### What is the P/E ratio of Glenmark Pharmaceuticals?

Glenmark Pharmaceuticals trades at a trailing P/E of 45.5. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 54.6.

### What is the ROE and ROCE of Glenmark Pharmaceuticals?

Return on equity was 13.0% in FY26 and return on capital employed was 33.0% in FY26 (consolidated figures).

### Is Glenmark Pharmaceuticals a debt-free company?

Glenmark Pharmaceuticals is close to debt-free: its debt-to-equity ratio was 0 in FY26.

### What were Glenmark Pharmaceuticals' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Glenmark Pharmaceuticals reported revenue of ₹3,932 Cr, +28.5% year on year, and net profit of ₹483 Cr, +928.0% year on year.

### How has Glenmark Pharmaceuticals stock performed over the last year?

Glenmark Pharmaceuticals' share price has risen 16.4% over the past year, −0.6% over three months and −10.5% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Glenmark Pharmaceuticals?

As of 30 Jun 2026: promoters 46.65%, foreign institutions 20.89%, domestic institutions 18.60%, non-institutions 13.81%.

### Who are Glenmark Pharmaceuticals' competitors?

The listed Pharma & Healthcare companies closest to Glenmark Pharmaceuticals by market cap are Max Healthcare Institute, Alkem Laboratories, Aster DM Health, Fortis Healthcare, Abbott India and Biocon.

### Is Glenmark Pharmaceuticals a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Glenmark Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GLENMARK against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.